Skip to main content
. 2017 Jan 3;6(2):e1274477. doi: 10.1080/2162402X.2016.1274477

Figure 5.

Figure 5.

High ESR1 expression is not associated with IDO1 promoter methylation and reduced IDO1 expression in cervical and endometrial carcinoma. (A) IDO1 mRNA expression is higher in ESR1 high (n = 152, higher than the median ESR1 expression) than ESR1 low (n = 153, equal or lower than the median ESR1 expression) cervical cancers (TCGA, cervical squamous cell carcinoma and endocervical adenocarcinoma; Student's t-test, **p < 0.01). (B) The DNA methylation at cg10262052 inversely correlates with IDO1 mRNA expression derived from TCGA (n = 305, Spearman's rank correlation). (C) The DNA methylation level of cg10262052 does not differ between ESR1 low (n = 153) compared with ESR1 high (n = 152) cervical cancers (TCGA, cervical squamous cell carcinoma and endocervical adenocarcinoma, Mann–Whitney U test). (D) IDO1 mRNA expression does not differ between ESR1 low (n = 87, equal and lower than the median ESR1 expression) compared with ESR1 high (n = 86, higher than the median ESR1 expression) human endometrial carcinoma tissues derived from TCGA uterine corpus endometrial carcinoma RNASeq data; Student's t-test. (E) The DNA methylation at cg10262052 does not correlate with IDO1 mRNA expression derived from TCGA uterine corpus endometrial carcinoma (n = 173, Spearman's rank correlation). (F) The DNA methylation level of cg10262052 is lower in ESR1 high (n = 86) compared with ESR1 low (n = 87) endometrial carcinomas (TCGA, uterine corpus endometrial carcinoma, Mann–Whitney U test). Box plots represent the medians and the 75% and 25% percentiles. Whiskers extend to min and max values.